59 citations
,
April 2016 in “Breast Cancer Research and Treatment” Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
January 2015 in “Faculty of 1000 Research Ltd” BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.
1 citations
,
January 2020 in “Seoul National University Open Repository (Seoul National University)” PDE3 inhibitor may help treat hair loss by promoting hair growth.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
2 citations
,
August 2017 in “Drug and therapeutics bulletin” Strontium ranelate is no longer available for treatment.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
1 citations
,
May 2025 in “Natural Products and Bioprospecting” PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
11 citations
,
January 1991 in “Urology” New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
1 citations
,
April 2020 in “Journal of The European Academy of Dermatology and Venereology” Drugs like PDEI may help hair disorders like AGA.
24 citations
,
April 2013 in “PLOS ONE” TNFα, IFNγ, and Substance P significantly affect prolactin levels in human skin, suggesting new treatments for skin and hair conditions.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
11 citations
,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
20 citations
,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
29 citations
,
July 2008 in “British Journal of Dermatology” The patient had paraneoplastic pemphigus without mucosal involvement.
October 2025 in “Journal of the Endocrine Society” Hormonal imbalances can cause heart rhythm issues, so checking hormone levels is crucial.
37 citations
,
March 2010 in “British Journal of Dermatology” Oestrogen and thyrotropin-releasing hormone affect prolactin and its receptor in human skin and hair, suggesting new treatment options for related conditions.
September 2025 in “Cureus” GLP-1 agonists may help treat certain skin conditions.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
May 2026 in “Dermatologic Surgery” GLP-1RAs may cause hair loss but could also help regrow hair in some cases.
24 citations
,
September 2014 in “PloS one” Thyroid hormone receptors are essential for hair growth and wound healing.